Hosted on MSN12m
EC approves CSL’s Andembry to stop hereditary angioedema attacks
CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...
pharmaphorum9h
EU approves CSL's once-monthly HAE drug Andembry
CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...
PMLiVE10h
EC approves CSL’s Andembry to prevent hereditary angioedema attacks
The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...
PharmaTimes1d
Andembry treatment approved across Europe
Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ...
Older Koreans' spending on age-related diseases jumps 28% to $4.6 bil. over past 5 years
Korea is expected to spend around 6 trillion won ($4.6 billion) this year on treating diseases related to aging such as ...
Portugal approves daily oral therapy for hereditary angioedema
RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX), a biotechnology company with impressive revenue growth of nearly 30% over the last twelve months, has announced that ...
BioCryst Launches ORLADEYO® (berotralstat) in Portugal
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® ...
Le Lézard4d
KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting
KalVista Pharmaceuticals, Inc. , today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 ...